Biotech
STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
Here is some of what you may have missed from the world's largest cancer research meeting.
Tag
ASCO
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
Health
STAT+: At the world’s largest cancer research meeting, data briefly took a backseat to grief
At the world's largest cancer research meeting, new data were plentiful. But this year, there was also a focus on grief.
Biotech
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
Biotech
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
Biotech
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Biotech
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
Biotech
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Biotech
STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
Biotech
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Biotech
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
The Readout LOUD
Biotech exec Jeremy Levin on the industry’s strategic turning point
This week on "The Readout LOUD," longtime biotech exec Jeremy Levin talks about his new book and the industry's strategic turning point. Listen now.